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Elevated serum antibody responses to synthetic mycobacterial lipid 
antigens among UK farmers: an indication of exposure to 
environmental mycobacteria? 
Alison Jones,b Carys A. Davies,a  Samuel Fitch,a Juma’a R. Al Dulayymi,b Christopher 
D.Gwenin,b,c James Gibbons,b  A. Prysor Williams,b and Mark S. Baird,a* 
Abstract  Background: Mycobacterial cells contain complex mixtures of mycolic acid esters. These can be used 
as antigens recognised by antibodies in the serum of individuals with active tuberculosis, caused by 
Mycobacterium tuberculosis. In high burden populations, a significant number of false positives are observed; 
possibly these antigens are also recognised by antibodies generated by other mycobacterial infections, 
particularly ubiquitous ‘environmental mycobacteria’. This suggests similar responses may be observed in a low 
burden TB population, particularly in groups regularly exposed to mycobacteria. Methods: ELISA using single 
synthetic trehalose mycolates corresponding to major classes in many mycobacteria was used to detect antibodies 
in serum of individuals with no known mycobacterial infection, comprising farmers, abattoir workers, and rural 
and urban populations. Results: Serum from four Welsh or Scottish cohorts showed lower (with some antigens 
significantly lower) median responses than those reported for TB negatives from high-burden TB populations, 
and significantly lower responses than those with active TB. A small fraction, particularly older farmers, showed 
strong responses. A second study examined BCG vaccinated and non-vaccinated farmers and non-farmers. 
Farmers gave significantly higher median responses than non-farmers with three of five antigens, while there was 
no significant difference between vaccinated or non-vaccinated for either farmer or non-farmer groups. 
Conclusions: This initial study shows that serodiagnosis with mycobacterial lipid antigens can detect antibodies 
in a population sub-group that is significantly exposed to mycobacteria, in an assay that is not interfered with by 
vaccination. Given the links between mycobacterial exposure and a range of immune system diseases, further 
understanding such responses may provide a new opportunity for monitoring public health and directing 
treatment.
 Introduction 
Mycobacteria contain characteristic long chain fatty acids, 
mycolic acids (MA) (Figure 1), often comprising 90 - 100 
carbon atoms,1-6 and present as very complex mixtures of 
different structural classes (X and Y), each normally present 
as an homologous series differing by two methylene groups. 
The common groups Y (Figure 1) are cis-alkenes and cis-
cyclopropanes, and trans-alkenes and trans-cyclopropanes 
with a methyl substituent on the adjacent carbon. Common 
groups X are cis-alkenes and cyclopropanes, trans-alkenes 
with an adjacent methyl group on the carbon distal from the 
hydroxy acid, and -CH(Me)CH(OMe)- or –CH(Me)CO- 
groups; the absolute stereochemistry of these substituents is 
now largely defined.6 The detailed composition of these 
mixtures provides a fingerprint for the particular 
mycobacterium.3,4 MA are commonly bound to the cell wall 
as penta-arabinose tetramycolates, non-wall bound, often as 
trehalose dimycolates (TDM) and monomycolates (TMM), 
and also as free MA.  Natural mixtures of free MA cause 
inflammatory immune system responses; similar effects are 
seen with single synthetic MA, depending subtly on the 
structure.7,8 Natural mixtures of MA esters have very 
significant effects on cytokines and chemokines - TDM is a 
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major component of Freund’s total adjuvant,9 while BCG 
vaccine is an extract of modified cells.10 The apparent link 
between BCG vaccination and the control of viral infections 
such as Covid-19 has been highlighted.11 BCG vaccine has 
been shown to reduce the severity of infections by other 
viruses with similar structure, reducing yellow fever vaccine 
viraemia,12 and the severity of mengovirus infection.13,14 BCG 
vaccine also has beneficial nonspecific effects on the immune 
system that protect against a wide range of other infections 







Meromycolate Moiety Mycolic Motif
[ X ] = Distal position
[ Y ] = Proximal position
a
 
Figure 1: Typical mycolic acid structure 
Single synthetic MA esters also show inflammatory 
properties and adjuvant potential, which depend on detailed 
structure,16 while single synthetic MA esters modulate the 
responses of CD1b-restricted GEM T cells depending on the 
mero-mycolate chain.17  
The recognition of  natural mixtures of MA by antibodies in 
infected serum has been applied in serodiagnosis of 
tuberculosis;18 complex mixtures of trehalose esters of MA 
(TDM) isolated from Mycobacterium tuberculosis (MTb) or 
Mycobacterium avium complex (MAC) differentiate the two 
infections.19-24 However, the WHO evaluated a large set of 
serodiagnostic assays and indicated that none met its required 
standards; it indicated, however, that a serodagnostic mthod 
that did work would be very valuable.25 Individual synthetic 
TDMs comprising different classes of MA are also recognised 
in enzyme-linked immunosorbent assays (ELISA) by 
antibodies in the serum of patients with active TB.26 The 
sensitivity (correct positives) and specificity (correct 
negatives) obtained using serum from patients from high TB-
burden countries and showing symptoms of disease, but 
clinically diagnosed with (TB+) or without (TB-) active 
disease, depend on the detailed substituents X and Y of the 
MA (Figure 1), and on their stereochemistry.26 From an 
initial group of some 15 synthetic TDMs and TMMs from 
different classes of synthetic MA, optimal values of around 
85 and 85 % sensitivity/specificity were obtained with single 
antigens (Figure 2); the performance of antigens n3, n28, 
n32,  n1, and n39 was rather similar, but in each case 
somewhat better than that of natural MTb TDM. Combination 
of the results with single antigens gave increased 
performance.26 Nonetheless, serum samples from some TB- 
patients consistently showed responses to each of these lipid 
antigens; one explanation is that, because complex mixtures 
of MA are present in all mycobacteria, there is a cross-
reactivity and the antigens also bind to antibodies generated 
by exposure to other organisms, such as ubiquitous NTM.27 
Another possibility is that there is a higher background 
response to such lipid antigens in a high burden population, 
particularly in individuals showing at least some symptoms of 
TB.   
Although tuberculosis remains a major global killer, 
infections by ‘non-tuberculous’ environmental mycobacteria 
(NTM), such as MAC, are increasing across the world.28 
Apparent links have been reported between exposure to 
mycobacteria and a number of diseases (eg., the observation 
of elevated levels of Mycobacterium avium paratuberculosis 
(MAP) in some Crohn’s patients,27 the link between NTM 
and bronchiostasis,30 and infection with Mycobacterium 
abscessus in cystic fibrosis patients.31 Moreover, there is an 
increasing problem of infections by MAC in ageing 
populations,28,32 and by Mycobacterium malmoense;33 both 
are commonly found in water and soil. We were interested 
therefore to determine whether exposure to environmental 
mycobacteria generates antibodies to cell wall lipids in a low 
TB burden  population and, in turn, to responses to MA-based 
antigens in ELISA.   
We report studies of two sets of serum samples, the first from 
individuals living in Wales or Scotland, originally collected 
for a study of Escherichia coli in farmers and abattoir 
workers,34 the second from a cohort of Welsh farmers and 



























































































































Figure 2: Antigens known to distinguish active TB from not 
active TB in high burden populations,26 and used in this study. 
 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
Study design and methods 
The serum samples 
The first set of 378 sera,34 were used under an appropriate 
ethical approval.35 The Welsh samples were divided into four 
broad sets, those from: i) farmers (WF); ii) abattoir workers 
(WA); iii) people living in rural Wales (WR); iv) people 
living in urban Wales (WU). The Scottish samples were 























378 UK samples with 
no known active TB
 
Scheme 1: Study plan: initial study 
  
The results were compared with those reported, using the 
same ELISA method, with serum from patients primarily 
from high burden TB countries, showing symptoms of disease 
but clinically diagnosed as active (TB+) or not active (TB-). 
These were provided by the WHO from the 
UNICEF/UNDP/World Bank/WHO Special Programme 
for Research and Training in Tropical Diseases TB 
Specimen Bank (labelled as WHO samples).26 
The second study used serum collected, with appropriate 
ethical approval,36 from farmers and non-farmers in Wales. 
The information collected included the BCG vaccination 
status of each individual (Scheme 2). 
240 serum samples from Wales
165 non-farmers 75 farmers
67 not vaccinated 91 vaccinated 6 unsure 19 not vaccinated 55vaccinated 1 unsure
 
Scheme 2: Second study: Welsh farmers and non-farmers 
with vaccination status 
Those with unknown BCG vaccination status were excluded 
from the calculations in respect of this, but were included in 
overall calculations of medians and total responses. 
The study demographics are given in ESI (Table S1). 
The ELISA method26 
ELISA were carried out in 96-well flat-bottomed polystyrene 
micro-plates.  Antigens were dissolved in hexane to give 
concentration of 15 µg/ml.  50 µl of this solution was added 
to each well, and the solvent was left to evaporate at room 
temperature. Control wells were coated with hexane (50 µl / 
well) only.  Blocking was done by adding 400 µl of 0.5 % 
casein/PBS buffer (pH = 7.4) to each well, and the plates 
were incubated at 25 ºC for 30 minutes.  The buffer was 
aspirated and any excess was flicked out until the plates were 
dry.  Serum (1 in 20 dilution in casein/PBS buffer) (50 µl / 
well) was added and incubated at 25 ºC for 1 hour. The plates 
were washed with 400 µl casein/PBS buffer 3 times using an 
automatic washer, and any excess buffer was flicked out onto 
a paper towel until dry.  Secondary antibody (anti-human IgG 
(Fc specific) peroxidise conjugated antibody produced in goat 
(Aldrich) (diluted to a concentration of 1:2000 in casein/PBS 
buffer) (50 µl / well) was added, and incubated at 25 ºC for 30 
minutes.  The plates were again washed 3 times with 400 µl 
casein/PBS buffer, and any excess buffer was flicked out.  
OPD substrate (50 µl / well) (o-phenylenediamine (1 mg / ml) 
and H2O2 (0.8 mg / ml) in 0.1 M citrate buffer) were then 
added, and the plates were incubated for 30 minutes at 25 ºC.  
The colour reaction was terminated by adding 2.5 M H2SO4 
(50 µl / well), and the absorbance was read at 492nm. ELISA 
responses above 3 should not be treated as quantitative. 
Absorbances reported have not been adjusted in this paper, 
for example by removing a standard background. The assays 
were run blind. 
 
The Antigens 
The antigens used were as in the earlier TB study,26 and cover 
the three main classes of MA present in M. tuberculosis (α-, 
methoxy and keto). They were selected in that study from a 
wider set of some 15 synthetic TDMs and TMMs as giving 
the best sensitivity/specificity combination and were run with 
the largest sample set. They were chosen for this current 
study to provide the most direct comparison. They were 
synthesised by methods described before.37,38 Antigen n3 is  a 
trehalose dimycolate (TDM) of an α-mycolic acid 
corresponding the main chain lengths and stereochemistry of 
such compounds in M. tuberculosis. TDM n28 and the 
corresponding trehalose monomycolate (TMM) n32 and 
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TDM  n1 incorporate stereoisomers of the major chain length 
of TB methoxy-mycolic acid, but gave good sensitivity and 
specificity in the TB study.26 Compound n39 is the TDM of a 
keto-mycolic acid with the natural stereochemistry and chain 
lengths. Antigen n4 was not evaluated with the full set of 




The binding of synthetic antigens to antibodies in serum from 
the different groups within Wales and Scotland was compared 
to median responses (already published) from the WHO 
sample bank (described earlier).26 These were taken from 
people who had been referred to a clinic with some of the 
symptoms of tuberculosis. Those in the TB+ set were 
clinically diagnosed to have active disease and were culture 
positive; those in the TB- set were culture negative and were 
diagnosed as not having active disease.   
The median results for the ELISA assays for the six antigens, 
carried out in triplicate, are presented in Table 1, compared to 
the corresponding figures for WHO TB+ and TB- samples.26 
Table 1 also includes an analysis of the significance of 
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        Pairwise significance 






n3 n28 n32 n1 n39 
n4 
n3 n28 n32 n1 n39 n3 n28 n32 n1 n39 n3 n28 n32 n1 n39 
n4 
WA 35 0.56 0.3 0.25 0.4 0.43 0.49 *** *** *** *** *** ns ns ** ns *** ns ns ns ns * ns 
WF 45 0.65 0.4 0.42 0.6 0.79 0.58 *** *** *** *** *** ns ns Ns ns ***            
WR 19 0.29 0.3 0.27 0.5 0.52 0.29. *** *** *** *** *** ns ns Ns ns *** ns ns ns ns ns * 
WU 31 0.49 0.4 0.32 0.5 0.57 0.50 *** *** *** *** *** ns ns * ns *** ns ns ns ns ns ns 
Scotland 
SA 20 0.39 0.31 0.28 0.42 0.31 0.50 *** *** *** *** *** *** *** *** ns ns ns * ns ns ns ** 
SF 85 0.43 0.36 0.41 0.50 0.42 0.44 *** *** *** *** *** *** *** *** ns ns            
SR 48 0.25 0.26 0.28 0.36 0.27 0.33 *** *** *** *** *** *** *** *** * * ns ns ns ns ns ns 
SU 95 0.27 0.24 0.23 0.31 0.29 0.30 *** *** *** *** *** *** *** *** *** *** * ns *** ** * ns 
WHO 
TB- 247 0.90 0.72 0.70 0.68 0.55 -                 
TB+ 102 3.40 3.03 2.83 3.24 3.36 -                 
 
Table 1: Median absorbances for four classes of Welsh and Scottish serum from individuals with no known mycobacterial infection, compared to those for WHO TB+ and 
TB- samples.26 WA: Welsh abattoir; WF; Welsh farmers; WR: Welsh rural; WU: Welsh urban; SA: Scottish abattoir; SF: Scottish farmers; SR: Scottish rural; SU: Scottish 
Urban. Significance levels for each group are compared to WHO TB+, WHO TB- and farmers groups: ***:  p < .001; **: p < .005; *: p < .01.  Comparison to farmer 
responses is within each country set. All p-values are adjusted for multiple comparisons using the joint family-wise error rate. The antigen n4 was not evaluated against the 
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The results for individual serum samples are shown in the dot- plots in Figure 3. 
 
 
Figure 3:  Dot plots of responses for each set of serum samples with six antigens and the total response 
The total responses in the assays with each of the antigens were 
summed for each serum sample from Wales and ranked in 
descending order; 9 out of 44 farmer’s samples (ESI Table S2) 
showed total values above the WHO TB- median, and a large 
number of individual values above the individual medians. A small 
number of individual values were above the median reported for 
the WHO TB+ set. Table S3 (ESI) shows the same analysis for the 
Scottish samples, where two were above the WHO TB+ total 
response. A more detailed analysis of the responses of Welsh 
farmers is shown in Figure 4, which shows increasing responses 
with age. The Welsh farmer set was therefore reanalysed for those 
under 55 and those over 55. The difference is significant for 
antigen n32 (ESI Table S4). 
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Figure 4.   Distribution of ELISA responses for each set of Welsh samples by age in years for each single antigen and the total response, 
with trend lines 
The corresponding analysis by age for the WA, WR and WU 
groups is given in ESI (Figure S4). 
In the second study, a set of samples from farmers and non-
farmers collected in North Wales was analysed using five antigens, 
to determine whether or not previous vaccination with BCG would 
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Non-vaccinated   
BCG 
vaccinated 
Antigen Median Median p value Median Median p value median Median p value 
n3 0.28 0.21 0.0026 0.26 0.28 0.209 0.22 0.17 0.047 
n28 0.21 0.16 0.0081 0.18 0.28 0.623 0.17 0.16 0.888 
n32 0.24 0.21 0.4462 0.21 0.26 0.36 0.22 0.20 0.316 
n4 0.34 0.30 0.044 0.33 0.37 0.373 0.32 0.22 0.033 
n39 0.28 0.20 0.0014 0.27 0.33 0.25 0.22 0.17 0.198 
 
Table 2: Median responses for second set of serum samples from farmers and non-farmers in Wales. Significance figures compare 
all farmers with non-farmers and vaccinated and non-vaccinated samples within each set. 
 
The results for those samples with a total response higher than 
twice the overall median with all the antigens, ranked in order, 
are given in Table S5 (ESI). Two farmers and one non-farmer 
gave total responses above the WHO TB+ set. The highest 
responder (responses well above linear scale of instrument) had 
recently returned from a high burden TB country and was 
diagnosed with an ascaris worm infection; such infections are 
linked to changes in TB immunity.39 The distributions of 
responses for each set by age are given in Figure S6 (ESI). 
 
Discussion 
Natural mixtures of mycolic acids (MA) show wide-ranging 
effects on the immune system.40 They will, e.g., control asthma 
in an experimental mouse model; single synthetic MA are even 
more effective in this model and show differential effects on a 
range of cytokines and chemokines.41 Sugar esters such as 
TDM are known to show very strong effects in the immune 
system.16,17 In a similar way, MA have been shown to be 
antigenic to antibodies in the serum of people with active TB; 
natural mixtures of MA sugar esters provide a rather simpler 
distinction between TB+ and TB- samples, but such a method 
has to date not proved good enough to be accepted by the 
WHO.25  
To try to improve the performance of such approaches, we have 
examined the use of single synthetic mycolic acids and  their 
sugar esters.26 Synthetic antigens, identical to, or stereoisomeric 
with, major components of natural sugar esters, were coated on 
ELISA plates. These were treated with human serum, then with 
a labelled secondary human antibody, Ig(Fc) which was 
visualised by the addition of an oxidase; this gave good 
sensitivity and specificity in distinguishing clinically defined 
TB+ from TB- samples. There were subtle differences between 
the responses to a set of 15 different antigens, but five provided 
the best combinations of sensitivity and specificity – a di-
cyclopropane α-MA TDM (n3), a keto-MA TDM (n39), both 
with the natural absolute stereochemistry, methoxy-MA TDM 
(n28) and TMM (n32), with the opposite absolute cyclopropane 
stereochemistry to the natural molecule, and methoxy-MA 
TDM (n1), with the opposite absolute distal methoxy fragment 
stereochemistry.38 However, within the WHO TB- serum set, 
there were a number of apparent false positives with each 
antigen, perhaps partly due to infection with NTM, such as M. 
abscessus, MAC or MAP, or indeed bovine TB.  
We therefore report the application of the same synthetic lipid 
antigens in ELISA using a series of human serum samples with 
no known mycobacterial infection, to probe the baseline signal 
for a country without a high level of TB, and to determine 
whether any pattern could be identified for any serum samples 
giving high signals. 
The median responses for the all sub-groups of Welsh and 
Scottish samples were significantly lower than the TB+ 
samples (***, Table 1). As in the earlier TB study,26 all five 
antigens gave broadly similar patterns of response, largely 
independent of the nature of the distal group (Y, Figure 1) or 
absolute stereochemistry. In the Welsh samples, medians were 
generally lower than those of the TB- samples, though only 
significantly so for antigen n32 with WA and WU sets; antigen 
n39 was significantly different from TB-, except for the WF 
when it was higher (***). The WA, WU and WR groups gave 
lower responses than WF with all antigens, but not significantly 
so except for WA with n39 and WR with n4. It is interesting to 
note that n39 is the TDM of a keto-MA, which was marginally 
the best antigen in the earlier TB study.26  
However, the lack of statistical significance hid large sample to 
sample differences. Thus, when the results from the Welsh 
samples were ranked by total response to all the antigens, and 
those above the TB- median were selected (ESI Table S2), 
seven of the top eight samples were from farmers. No samples 
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gave a total value higher than the median for the WHO+ set. 
However, while the median for farmers under 55 was very 
similar to that for non-farmers, that for farmers over 55 years 
old was significantly higher as seen by the trend lines in Figure 
4. In the case of n32 this difference was significant (p = 0.006, 
ESI, Table S4). This response suggests elevated levels of 
antibodies to mycobacterial lipids. It is possible they may 
reflect a lifetime of exposure to environmental mycobacteria, 
including MAP, and to animals carrying bovine TB, or simply 
reflect the trend seen worldwide,42-44 exemplified in the 
US,,45,46 Canada,47 Japan,48 and Korea,28 that NTM infections in 
the older population groups are growing considerably. There 
was no such clear trend with the other sets sets of Welsh 
samples (ESI, Figure S4). 
It is interesting that in this set of samples, those from abattoir 
workers were generally similar to urban and rural samples, 
perhaps reflecting the controlled environment in which they 
work. The abattoir worker with the most elevated response was 
the individual responsible for disposing of all intestinal 
material.   
In the case of the Scottish set, there was a significant difference 
across all groups and antigen from the WHO+ medians. All 
groups also showed a significant difference to the WHO- 
median with three of the five antigens, but no significant 
difference with SA and SF sets with antigens n1 and n39. 
Moreover, the medians for the SF group were below those for 
the WHO- group, whereas for the WF it was higher. When the 
results for all the samples were ranked by their total response 
(ESI Table S3), only 14 of the 42 samples with total responses 
above the WHO TB- set were farmers. One farmer and one 
abattoir worker gave total responses above the WHO TB+ 
median. The distribution of responses did not show the increase 
with age for the Scottish farmers (ESI Table S4, Figure S4). It 
is possible that this reflects to some extent the lack of bovine 
tuberculosis in Scotland, and therefore exposure of the SF set to 
Mycobacterium bovis, but at this stage it is not possible to rule 
out other factors. 
In the second study, serum samples collected from groups of 
farmers and non-farmers from Wales, with known BCG 
vaccination status, were examined by ELISA using five 
antigens (Table 2). The medians for the farmer set were 
significantly higher than for the non-farmer set for three of the 
five antigens. When the total median responses were ranked in 
order, 14 (out of 76) farmers and 15 (out of 164) non-farmers 
gave values more than the TB- median and three were above 
the TB+ median (ESI Table S5). Interestingly, two of the top 
five responses were from non-farmers whom had recently 
returned from high burden TB areas, suggesting that, at least in 
these cases, the responses might be caused by exposure to Mtb. 
There were no significant differences between the median 
responses with any antigen for vaccinated and un-vaccinated 
groups of either farmers or non-farmers. This supports the 
result of the earlier TB diagnostic study, that BCG vaccination 
does not lead to false positives.26 There was some evidence of 
an increased response in farmers with age (ESI Figure S6) but 
there were not many older farmers in this cohort..  
Within this second group, one sample stood out, giving much 
higher responses than any other sample in this group or in the 
earlier study of samples from patients with active 
tuberculosis.26 This sample was from an individual diagnosed 
as having an ascaris infection, and who had recently returned 
from a country where TB is endemic. Such infections are 
known to cause significant changes to the immune system.39.49   
The compounds present in the cell walls of mycobacteria, and 
their synthetic analogues as used in this work, are known to 
show very strong effects on a range of cytokines and 
chemokines and may provide a link between exposure to 
mycobacteria and the development of immune system diseases. 
A more detailed understanding of why the serum of some 
individuals, with no known mycobacterial infection, appear to 
bind strongly to these antigens – and potentially to a wider 
range of characteristic mycobacterial antigens such as diene 
mycolic acids,50 and wax ester mycolates51  -  may offer the 
potential for early warning of immune system changes that 
could in time lead to disease, or of existing disease that has 
caused changes to immune system responses. It is also 
necessary to rule out responses to antibodies that are cross-
reactive to non-MA ester antigens, such as those responding 
both to cholesterol and free mycolic acids.52 
Conclusions 
Serum from individuals with no known mycobacterial infection 
taken from four groups of people living in Wales and Scotland 
showed median responses that were somewhat lower than those 
reported for a population of individuals from TB endemic 
countries having TB symptoms, but clinically diagnosed as TB-
, and significantly lower responses than a population with 
active TB. However, some individuals, particularly from a 
group of farmers, showed very high responses. Within the 
farmers set, responses were significantly higher with some 
antigens for individuals over 55 years old. It is dangerous to 
draw firm conclusions from this initial study, but this group has 
clearly been exposed to environmental mycobacteria for a 
longer period, and also are in the age group where NTM 
infections become more prominent. 
A second study involved groups of farmers and non-farmers 
from Wales, and including those known to have been 
vaccinated with BCG, and those not vaccinated. The farmer 
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cohort showed significantly lower responses with three of five 
antigens, but there was no significant difference between BCG 
vaccinated or non-vaccinated farmers, or the corresponding 
non-farmers.  
Over the 618 samples evaluated, only five gave total signals 
exceeding the WHO TB+ median. This suggests that false 
positives would not represent a major problem in serodiagnosis 
of TB using lipid antigens in a low burden population. 
Moreover, the lack of effect of vaccination suggests that such 
an assay would ‘not be interfered with by vaccination’ (NIVA). 
Whatever the reason for the differences in the responses for 
farmers from the other sub-sets, there appears to be a strong 
case for understanding them further, and probing their possible 
link to particular exposure to mycobacteria, or to existing or 
developing infections. It is possible that routine measurement 
of responses of antibodies in serum to lipid antigens might 
provide a rapid means for guiding public health practices, 
identifying the early stage infection and controlling exposure of 
at-risk population groups.  The links between infection by 
mycobacteria and the virulence of disease, highlighted by the 
apparent link between BCG vaccination, Covid-19 and the 
control of viral infections suggests this deserves further study.  
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